Xin Ye

Director, Oncology Precision Medicine & Diagnostic Johnson & Johnson

Seminars

Wednesday 12th November 2025
Unlocking Clinical Insights: The Role of MRD as an Endpoint, Technologies, & Regulatory Perspectives
2:55 pm
  • How can MRD serve as a reliable surrogate endpoint to predict long-term clinical benefits in hematologic malignancies?
  • What are the latest advancements in detection technologies that can enhance the sensitivity and reproducibility of MRD measurement?
  • How are regulatory agencies evolving their frameworks to accept MRD as endpoint in clinical trials?
Xin Ye